fortune gems 3 slot
Ancient meets modern as a new subway in Greece showcases archaeological treasures THESSALONIKI, Greece (AP) — Thessaloniki, Greece’s second-largest city, is opening a new subway system, blending ancient archaeological treasures with modern transit technology like driverless trains and platform screen doors. The project, which began in 2003, uncovered over 300,000 artifacts, including a Roman-era thoroughfare and Byzantine relics, many of which are now displayed in its 13 stations. Despite delays caused by preserving these findings, the inaugural line has been completed, with a second line set to open next year. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. At least 19 people are sick in Minnesota from ground beef tied to E. coli recall U.S. health officials say at least 19 people in Minnesota have been sickened by E. coli poisoning tied to a national recall of more than 167,000 pounds of potentially tainted ground beef. Detroit-based Wolverine Packing Co. recalled the meat this week after Minnesota state agriculture officials reported multiple illnesses and found that a sample of the product tested positive for E. coli O157:H7, which can cause life-threatening infections. Symptoms of E. coli poisoning include fever, vomiting, diarrhea and signs of dehydration. Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. Actor Jonathan Majors’ ex-girlfriend drops assault and defamation lawsuit against once-rising star NEW YORK (AP) — Jonathan Majors’ ex-girlfriend has dropped her assault and defamation lawsuit against the once-rising Hollywood star after reaching a settlement. Lawyers for Majors and Grace Jabbari agreed to dismiss the case with prejudice Thursday. Jabbari is a British dancer who had accused Majors of subjecting her to escalating incidents of physical and verbal abuse during their relationship. Representatives for Majors didn’t respond to emails seeking comment Friday. Jabbari’s lawyer said the suit was “favorably settled” and her client is moving on with “her head held high.” Majors was convicted of misdemeanor assault and harassment last December and sentenced to a yearlong counseling program. Hyundai, Kia recall over 208,000 electric vehicles to fix problem that can cause loss of power DETROIT (AP) — Hyundai and Kia are recalling over 208,000 electric vehicles to fix a pesky problem that can cause loss of drive power, increasing the risk of a crash. The recalls cover more than 145,000 Hyundai and Genesis vehicles including the 2022 through 2024 Ioniq 5, the 2023 through 2025 Ioniq 6, GV60 and GV70, and the 2023 and 2024 G80. Also included are nearly 63,000 Kia EV 6 vehicles from 2022 through 2024. The affiliated Korean automakers say in government documents that a transistor in a charging control unit can be damaged and stop charging the 12-volt battery. Dealers will inspect and replace the control unit and a fuse if needed. They also will update software. Christmas TV movies are in their Taylor Swift era, with two Swift-inspired films airing this year Two of the new holiday movies coming to TV this season have a Taylor Swift connection that her fans would have no problem decoding. “Christmas in the Spotlight” debuts Saturday on Lifetime. It stars Jessica Lord as the world’s biggest pop star and Laith Wallschleger, playing a pro football player, who meet and fall in love, not unlike Swift and her boyfriend, Kansas City Chiefs tight end Travis Kelce. On Nov. 30, Hallmark will air “Holiday Touchdown: A Chiefs Love Story.” Instead of a nod to Swift, it’s an ode to family traditions and bonding, like rooting for a sports team. Hallmark’s headquarters is also in Kansas City. Top football recruit Bryce Underwood changes commitment to Michigan instead of LSU, AP source says ANN ARBOR, Mich. (AP) — Top football recruit Bryce Underwood has flipped to Michigan after pledging to play at LSU. That's according to a person familiar with the situation who spoke to The Associated Press on condition of anonymity because they were not authorized to share the recruit’s plans to join the Wolverines. Underwood pinned a post on his Instagram account, showing a post in which On3.com reported that he has committed to Michigan. The 6-foot-3 quarterback played at Belleville High School about 15 miles east of Michigan's campus, and told LSU nearly a year ago he intended to enroll there. Emperor penguin released at sea 20 days after waddling onto Australian beach MELBOURNE, Australia (AP) — The only emperor penguin known to have swum from Antarctica to Australia has been released at sea 20 days after he waddled ashore on a popular tourist beach. The adult male was found on Nov. 1 on sand dunes in temperate southwest Australia about 2,200 miles north of the Antarctic coast. He was released Wednesday from a boat that traveled several hours from Western Australia state's most southerly city of Albany. His caregiver Carol Biddulph wasn't sure at first if the penguin would live. She said a mirror was important to his rehabilitation because they provide a sense of company. Biddulph said: “They’re social birds and he stands next to the mirror most of the time.” Shohei Ohtani wins third MVP award, first in NL. Aaron Judge earns second AL honor in 3 seasons NEW YORK (AP) — Shohei Ohtani won his third Most Valuable Player Award and first in the National League, and Aaron Judge earned his second American League honor on Thursday. Ohtani was a unanimous MVP for the third time, receiving all 30 first-place votes and 420 points in voting by the Baseball Writers’ Association of America. New York Mets shortstop Francisco Lindor was second with 263 points and Arizona second baseman Ketel Marte third with 229. Judge was a unanimous pick for the first time. Kansas City shortstop Bobby Witt Jr. got all 30 second-place votes for 270 points, and Yankees outfielder Juan Soto was third with 21 third-place votes and 229 points.
Judges warn of ‘serious logistical problems’ with assisted dying bill"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.The man charged in the killing of the CEO of UnitedHealthcare reported in online writings over a period of years that he had been navigating a series of life-altering health problems. In posts on a Reddit account, the man, Luigi Mangione , said back pain that had once been a minor issue in his life grew more extreme in 2022 after he went surfing, then grew worse again a few weeks later when he slipped on a piece of paper. He reported persistent problems, including pain when he sat down, twitching leg muscles, and numbness in his groin and bladder. Suspect Luigi Mangione yells as he is taken into the Blair County Courthouse in Hollidaysburg, Pennyslvania. Credit: AP He shared details that friends have corroborated, writing that he had a spinal fusion surgery in July 2023. He wrote that within days he did not need pain meds and could sit, stand and walk just fine. “The surgery wasn’t nearly as scary as I made it out to be in my head, and I knew it was the right decision within a week,” he wrote in one Reddit post. He went on to encourage others to consider such surgery, pointing to athletes who had done so. An X-ray that he posted on another social media account showed a spinal fusion. The back pain was not his only struggle. He wrote at times about “brain fog” that had worsened during his college years, making studying more difficult. Doctors could not seem to figure out what was happening, he reported. “It’s absolutely brutal to have such a life-halting issue,” he wrote. He also posted on a page for people dealing with irritable bowel syndrome, saying that he had undergone some testing for the condition. He said the testing had been covered by Blue Cross Blue Shield — his only reference in the Reddit writings to insurance coverage. After the back surgery, he returned to Hawaii, where he had previously been living, but by the spring of this year, he had ceased communications with most friends and family members. His family reached out to his friends in recent months in hopes of finding him. Arraignment photo of Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson. Credit: AP The suspect’s comment history on Reddit gives other clues to his personal life and pursuits. He was an active commenter in the OneBag subreddit, a community that “promotes urban travel with the philosophy of carrying less” and focuses on different types of backpacks and travel gear. Photos released by the New York Police Department of the assailant in the UnitedHealthcare shooting showed what its maker identified as a backpack by Peak Design, a brand that was widely discussed in the OneBag subreddit. The suspect also posted to the Magfest subreddit, a community dedicated to a gaming subculture and festival held annually in Maryland, where he grew up. Sarah Nehemiah, a friend during his time in Hawaii, described him as an avid gamer and Pokémon enthusiast. He posted enthusiastically to the Pokémon Go subreddit, a forum dedicated to the popular mobile augmented reality game in which users catch virtual Pokémon using their mobile phones. Police have charged Luigi Mangione with the murder of Brian Thompson. Credit: Facebook Gaming has long been a part of the suspect’s life. He spent much of his childhood creating games and later went into the tech and gaming industry, working as an intern at the company that created the enormously popular Civilization game franchise. The Reddit account has since been deleted by the company, but archived versions of the posts were reviewed by The New York Times . A Reddit spokesperson said its policy was to suspend accounts that may potentially be related to suspects in high-profile criminal investigations. A 2016 photo of Luigi Mangione taken from his social media accounts. Credit: Facebook Tech companies typically suspend accounts in such cases to avoid impersonation. On Monday, Meta suspended the suspect’s accounts on Facebook and Instagram. And GoodReads, a site dedicated to chronicling a person’s reading activities, suspended his account the same day. This article originally appeared in The New York Times . Get a note directly from our foreign correspondents on what’s making headlines around the world. Sign up for the weekly What in the World newsletter here .
Joe Burrow's home broken into during Monday Night Football in latest pro-athlete home invasionEvaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate TM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.comNicaragua OKs reform to boost powers of president, wife
Garrett Wilson clearly isn't happy. And his future with the New York Jets seems murkier than ever. The star wide receiver wants to win more than anything, but three losing seasons to start his NFL career have taken their toll. Wilson has been an extremely bright spot for the Jets during that span, setting team receiving records and establishing himself as one of the top players in the NFL at his position. He's the fourth-most targeted player in the league this season. But he still believes he could do more — and that he can help the Jets (4-11) win. Wilson had six catches for 54 yards on Sunday in New York's 19-9 loss to the Los Angeles Rams. Four of his seven targets came during the Jets' final drive. Davante Adams had 13 targets and clearly has been the favorite target of Aaron Rodgers — not surprising since they played together eight years in Green Bay. But Wilson has seemed almost an afterthought lately. "I don't know, to be honest with you, man," Wilson said after the game when asked why he wasn't more involved in the offense. "I've just got to go out and put my best foot forward and hope that things fall my way. I'd love to be involved, love to make an impact on the game, but if people see it differently, then it's out of my control. “So, just trying to do what I can do.” That came a few days after Wilson was noncommittal on whether he can see himself staying with the Jets long term if they offer him a contract extension after the season. He had a similar response after the game. “At the end of the day, we've got to find ways to get Garrett the ball more often,” interim coach Jeff Ulbrich said Monday. “He’s one of the best players on our team, if not one of the best players in this league, especially at his position, so the progression for a lot of different reasons from a coverage standpoint took (Rodgers) off Garrett, but at the same time, we've got to find ways to get him the ball, for sure.” Wilson is due for an extension after this season, but the Jets have control over his contract through the 2027 season. There are rumblings that Wilson, who ranks among the league leaders with 90 receptions and 987 yards receiving, could seek a trade. The Jets' next general manager and coach will have to make decisions on the futures of several players, including Rodgers, but Wilson also will be a priority in the team's offseason conversations. “If you weren’t frustrated, I think that would bother me to an extent,” Ulbrich said. “I think he’s just one of those ultimate competitors that wants the ball, not for selfish reasons. Just from the standpoint he knows he can help our team win if he does have the ball in his hands.” What’s working Fast starts. The Jets have scored touchdowns on their opening possession in each of their last two games after previously not doing so all season. What needs help With the team out of the playoff hunt, Ulbrich was aggressive. The Jets went for it on fourth down five times against the Rams and converted just twice. Two of the stops led to points for Los Angeles. After Breece Hall was stuffed on fourth-and-1 at the Jets 33 in the second quarter, the Rams kicked a field goal to tie it. On their first possession of the second half, the Jets went for it on a fourth-and-4 from the Rams 13 instead of kicking a field goal. But Rodgers' fade pass to Adams was incomplete, ending a 14-play, 78-yard drive. Los Angeles followed by kicking another tying field goal. Stock up CB D.J. Reed. The veteran defensive back has arguably been the Jets' best cornerback this season. Reed is scheduled to be a free agent during the coming offseason and could be in for a big payday. Whether to bring him back will be a major topic of conversation for the Jets' new regime. Stock down K Anders Carlson. He briefly provided some stability as the Jets' fourth kicker this season but has struggled lately. Carlson missed an extra point, his second of the season, and was wide right on a late 49-yard field goal try that would've made it a one-score game and given the Jets a chance at a comeback attempt against the Rams. Ulbrich said there's a chance there could be another change this week. Injuries Rookie LT Olu Fashanu is dealing with a foot injury. The first-round pick was seen on crutches after the game, but Ulbrich said Fashanu was still getting tests done to determine the severity of the injury. ... DT Quinnen Williams was inactive with a hamstring injury. He tested it before the game and was scratched. Ulbrich said there's a chance he'll play this week. ... CB Sauce Gardner (hamstring) and S Tony Adams (ankle) left the game with injuries. Key number 0 — The Jets scored 9 points and had no punts in the loss to Los Angeles. They joined the 1991 Colts — a 16-7 loss to the Patriots in the season opener — as the only teams in the Super Bowl era to score fewer than 10 points and not punt. What’s next The Jets travel for their last road game of the season to Buffalo, where they'll take on the AFC East rival Bills. ___ AP NFL: https://apnews.com/hub/NFL Dennis Waszak Jr., The Associated PressBiden says Assad's fall in Syria is a 'fundamental act of justice,' but 'a moment of risk'Indian billionaire Gautam Adani on Saturday said "attacks" on his company made it "stronger", days after US prosecutors accused him and other officials of fraud. The November 20 bombshell indictment in New York accused the industrialist and multiple subordinates of deliberately misleading international investors as part of a multi-million-dollar bribery scheme. Addressing the allegations for the first time, the 62-year-old tycoon said his conglomerate was committed to "world-class regulatory compliance". "What I can tell you is that every attack makes us stronger and every obstacle becomes a stepping stone for a more resilient Adani Group," he said at an awards ceremony in the northern Indian city of Jaipur. Adani is suspected of having participated in a $250 million scheme to bribe Indian officials for lucrative solar energy supply contracts. The billionaire, however, said nobody from his company had been charged with any violation of corruption laws or "any conspiracy to obstruct justice". The US Justice Department said Adani, his nephew Sagar Adani, and one other official were charged "with conspiracies to commit securities and wire fraud and substantive securities fraud". Five others were charged "with conspiracy to violate the Foreign Corrupt Practices Act," the department said. On Thursday, Adani's company said it had suffered a loss of nearly $55 billion in market capitalisation across its 11 listed companies since the US indictment was filed. With a business empire spanning coal, airports, cement and media, Adani Group has weathered previous corporate fraud allegations, suffering a similar stock rout last year. The conglomerate saw $150 billion wiped from its market value in 2023 after a report by short-seller Hindenburg Research accused it of "brazen" corporate fraud. Adani is a close ally of Hindu nationalist Prime Minister Narendra Modi and was at one point the world's second-richest man, and critics have long accused him of improperly benefitting from their relationship. ash/aha Get any of our free email newsletters — news headlines, sports, arts & entertainment, state legislature, CFD news, and more.
Celtic boss Brendan Rodgers played to gallery with SPFL pyro charge response – would he let the ned-mobs into his house?
The Latest: UnitedHealthcare shooting suspect contests his extradition back to New YorkShares of Japanese automaker Honda were on track for their best day in 16 years after it announced to buy back up to 1.1 trillion yen ($7 billion) of its shares on Monday amid merger talks with Nissan . > Philadelphia news 24/7: Watch NBC10 free wherever you are Nissan and Honda said they had begun official negotiations to merge , which could catapult them to the world's third-largest carmaker by sales. Honda also announced to buy back 24% of its issued shares by Dec. 23 next year. Its shares were last up 15.51%, and would clock their best day since October 2008, if gains hold. Nissan shares fell over 1%. The Honda-Nissan deal would focus on sharing knowledge and resources, achieving economies of scale and creating synergies, Honda CEO Toshihiro Mibe said . A holding company will be established as the parent organization for both Honda and Nissan, and will be listed on the Tokyo Stock Exchange. "These two companies, they are operating in the same market, and they have very similar brand images, they have very similar products," Hakan Dogu, chairman of Alagan Mobility Solutions, told CNBC on Tuesday. "The new management has a big challenge to differentiate the product range and also extend the business," he added. Discussions are set to conclude in June 2025. Nissan's strategic partner, Mitsubishi, has been given the opportunity to join the new group and is expected to make a decision by the end of January 2025. Honda reported 1.382 trillion yen in operating profit for the full year to March 2024, versus Nissan's 568.7 billion yen. The automakers would have a combined value of nearly $54 billion, with Honda's market capitalization contributing the greater $43 billion share. Analysts suggested that the potential merger stems from Nissan's financial struggles and the restructuring of its long-standing partnership with France's Renault. In its latest quarterly report, Nissan announced plans to cut 9,000 jobs and reduce its global production capacity by 20%. —CNBC's Jenni Reid contributed to this report.Albanese struggles to offload Dulwich Hill investment propertyA inert grenade gave a West Kelowna family quite the scare the morning of Dec. 23. Candice Loring took to social media around 11 a.m. after her family was evacuated and West Kelowna RCMP investigated the unmarked package. The incident ended quickly after RCMP were able to confirm the delivery was meant for a neighbour and a military paraphernalia collector. The device was not live and had been delivered to the wrong address. Loring has updated her post around 12:30 p.m. to say her family is returning home. The incident took place in the 2000-block of the Old Okanagan Highway.
Isaac Guerendo to miss 49ers' only full practice ahead of Rams gameJoe Burrow's home broken into during Monday Night Football in latest pro-athlete home invasion
Kate Moss splits from teetotal Nikolai Von Bismarck after 9 years as supermodel declares she wants ‘to have some fun’
Antitrust enforcement may lighten under TrumpThe Many Applications of Pressure Washing With Jay's Pressure LLC
Meet the 12 CFP Title Contenders: No. 11 SMUAmber Heard: Blake Lively complaint against Justin Baldoni all too familiar